Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain

Camilla Kristine Appel, Nicole Newell Scheff, Chi Tonglien Viet, Brian Schmidt, Anne Marie Heegaard

Research output: Contribution to journalArticle

Abstract

Bone cancer metastasis is extremely painful and decreases the quality of life of the affected patients. Available pharmacological treatments are not able to sufficiently ameliorate the pain, and as patients with cancer are living longer, new treatments for pain management are needed. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferases inhibitor, has analgesic properties in preclinical models of postsurgical and soft-tissue oral cancer pain by inducing an upregulation of endogenous opioids. In this study, we report that daily treatment with decitabine (2 µg/g, intraperitoneally) attenuated nociceptive behavior in the 4T1-luc2 mouse model of bone cancer pain. We hypothesized that the analgesic mechanism of decitabine involved activation of the endogenous opioid system through demethylation and reexpression of the transcriptionally silenced endothelin B receptor gene, Ednrb. Indeed, Ednrb was hypermethylated and transcriptionally silenced in the mouse model of bone cancer pain. We demonstrated that expression of Ednrb in the cancer cells lead to release of β-endorphin in the cell supernatant, which reduced the number of responsive dorsal root ganglia neurons in an opioid-dependent manner. Our study supports a role of demethylating drugs, such as decitabine, as unique pharmacological agents targeting the pain in the cancer microenvironment.

Original languageEnglish (US)
Pages (from-to)619-631
Number of pages13
JournalPain
Volume160
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

decitabine
Bone Neoplasms
Opioid Analgesics
Analgesics
Pharmacology
Endothelin B Receptors
Endorphins
Pain
Tumor Microenvironment
Mouth Neoplasms
Methyltransferases
Spinal Ganglia
Pain Management
Neoplasms
Up-Regulation
Therapeutics
Quality of Life
Cancer Pain
Neoplasm Metastasis
Neurons

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. / Appel, Camilla Kristine; Scheff, Nicole Newell; Viet, Chi Tonglien; Schmidt, Brian; Heegaard, Anne Marie.

In: Pain, Vol. 160, No. 3, 01.03.2019, p. 619-631.

Research output: Contribution to journalArticle

Appel, Camilla Kristine ; Scheff, Nicole Newell ; Viet, Chi Tonglien ; Schmidt, Brian ; Heegaard, Anne Marie. / Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. In: Pain. 2019 ; Vol. 160, No. 3. pp. 619-631.
@article{1c90bd77a6b84151ad72a9ad79d986c9,
title = "Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain",
abstract = "Bone cancer metastasis is extremely painful and decreases the quality of life of the affected patients. Available pharmacological treatments are not able to sufficiently ameliorate the pain, and as patients with cancer are living longer, new treatments for pain management are needed. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferases inhibitor, has analgesic properties in preclinical models of postsurgical and soft-tissue oral cancer pain by inducing an upregulation of endogenous opioids. In this study, we report that daily treatment with decitabine (2 µg/g, intraperitoneally) attenuated nociceptive behavior in the 4T1-luc2 mouse model of bone cancer pain. We hypothesized that the analgesic mechanism of decitabine involved activation of the endogenous opioid system through demethylation and reexpression of the transcriptionally silenced endothelin B receptor gene, Ednrb. Indeed, Ednrb was hypermethylated and transcriptionally silenced in the mouse model of bone cancer pain. We demonstrated that expression of Ednrb in the cancer cells lead to release of β-endorphin in the cell supernatant, which reduced the number of responsive dorsal root ganglia neurons in an opioid-dependent manner. Our study supports a role of demethylating drugs, such as decitabine, as unique pharmacological agents targeting the pain in the cancer microenvironment.",
author = "Appel, {Camilla Kristine} and Scheff, {Nicole Newell} and Viet, {Chi Tonglien} and Brian Schmidt and Heegaard, {Anne Marie}",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/j.pain.0000000000001442",
language = "English (US)",
volume = "160",
pages = "619--631",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain

AU - Appel, Camilla Kristine

AU - Scheff, Nicole Newell

AU - Viet, Chi Tonglien

AU - Schmidt, Brian

AU - Heegaard, Anne Marie

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Bone cancer metastasis is extremely painful and decreases the quality of life of the affected patients. Available pharmacological treatments are not able to sufficiently ameliorate the pain, and as patients with cancer are living longer, new treatments for pain management are needed. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferases inhibitor, has analgesic properties in preclinical models of postsurgical and soft-tissue oral cancer pain by inducing an upregulation of endogenous opioids. In this study, we report that daily treatment with decitabine (2 µg/g, intraperitoneally) attenuated nociceptive behavior in the 4T1-luc2 mouse model of bone cancer pain. We hypothesized that the analgesic mechanism of decitabine involved activation of the endogenous opioid system through demethylation and reexpression of the transcriptionally silenced endothelin B receptor gene, Ednrb. Indeed, Ednrb was hypermethylated and transcriptionally silenced in the mouse model of bone cancer pain. We demonstrated that expression of Ednrb in the cancer cells lead to release of β-endorphin in the cell supernatant, which reduced the number of responsive dorsal root ganglia neurons in an opioid-dependent manner. Our study supports a role of demethylating drugs, such as decitabine, as unique pharmacological agents targeting the pain in the cancer microenvironment.

AB - Bone cancer metastasis is extremely painful and decreases the quality of life of the affected patients. Available pharmacological treatments are not able to sufficiently ameliorate the pain, and as patients with cancer are living longer, new treatments for pain management are needed. Decitabine (5-aza-2'-deoxycytidine), a DNA methyltransferases inhibitor, has analgesic properties in preclinical models of postsurgical and soft-tissue oral cancer pain by inducing an upregulation of endogenous opioids. In this study, we report that daily treatment with decitabine (2 µg/g, intraperitoneally) attenuated nociceptive behavior in the 4T1-luc2 mouse model of bone cancer pain. We hypothesized that the analgesic mechanism of decitabine involved activation of the endogenous opioid system through demethylation and reexpression of the transcriptionally silenced endothelin B receptor gene, Ednrb. Indeed, Ednrb was hypermethylated and transcriptionally silenced in the mouse model of bone cancer pain. We demonstrated that expression of Ednrb in the cancer cells lead to release of β-endorphin in the cell supernatant, which reduced the number of responsive dorsal root ganglia neurons in an opioid-dependent manner. Our study supports a role of demethylating drugs, such as decitabine, as unique pharmacological agents targeting the pain in the cancer microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=85061590964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061590964&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000001442

DO - 10.1097/j.pain.0000000000001442

M3 - Article

C2 - 30422869

AN - SCOPUS:85061590964

VL - 160

SP - 619

EP - 631

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -